Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.

##STR00001##

The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.

There is provided as a biocide zinc or copper (II) salt having the general formula CH.sub.2C(R.sup.1)COO-M-OCOC.sub.6H.sub.3R.sup.2R.sup.4, wherein M is Zn or Cu, R.sup.1 is selected from the group comprising hydrogen and methyl, R.sup.2 is selected from the group comprising hydrogen and OH, R.sup.4 is selected from the group comprising hydrogen, alkyl and SO.sub.2OH group.

There is provided as a biocide zinc or copper (II) salt having the general formula CH.sub.2C(R.sup.1)COO-M-OCOC.sub.6H.sub.3R.sup.2R.sup.4, wherein M is Zn or Cu, R.sup.1 is selected from the group comprising hydrogen and methyl, R.sup.2 is selected from the group comprising hydrogen and OH, R.sup.4 is selected from the group comprising hydrogen, alkyl and SO.sub.2OH group.

A quantum dot composition includes a quantum dot, and a ligand bonded to a surface of the quantum dot, wherein the ligand includes a head portion bonded to the surface of the quantum dot and containing a polar solvent dissociative functional group, and a tail portion connected to the head portion. A quantum dot composition according to an embodiment is used to form an emission layer of a light emitting element to enhance luminous efficiency of the light emitting element including an emission layer formed through the quantum dot composition.

A quantum dot composition includes a quantum dot, and a ligand bonded to a surface of the quantum dot, wherein the ligand includes a head portion bonded to the surface of the quantum dot and containing a polar solvent dissociative functional group, and a tail portion connected to the head portion. A quantum dot composition according to an embodiment is used to form an emission layer of a light emitting element to enhance luminous efficiency of the light emitting element including an emission layer formed through the quantum dot composition.

The present invention relates to co-crystals of ibrutinib and a pharmaceutical composition comprising the same as well as a method of preparing the same.

The present invention relates to co-crystals of ibrutinib and a pharmaceutical composition comprising the same as well as a method of preparing the same.

The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT.sub.2 receptor agonists and uses in the treatment of diseases associated with a 5-HT.sub.2 receptor.

##STR00001##

The present disclosure relates generally to the field of nicotine delivery. The disclosure teaches a nicotine meta-salicylate. More specifically, the disclosure teaches a condensation nicotine aerosol where nicotine meta-salicylate is vaporized. This disclosure relates to aerosol nicotine delivery devices. The delivery devices can be activated by actuation mechanisms to vaporize thin films comprising a nicotine meta-salicylate. More particularly, this disclosure relates to thin films of nicotine salt with meta salicylic acid for the treatment of nicotine craving and for effecting smoking cessation.